Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine + Remimazolam for Painless Fiberoptic Bronchoscopy
ChiCTR2500110217Phase 4Not yet recruiting
- Sponsor
- Gansu Provincial People's Hospital
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oliceridine, sufentanil and remimazolam in procedural pain, pneumonia, bronchiectasis and 2 more (3 arms), sponsored by Gansu Provincial People's Hospital. Primary endpoint: Success Rate of Bronchoscopic Diagnosis and Treatment. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
oliceridinesufentanilremimazolam
03
Conditions
procedural painpneumoniabronchiectasislung nodule (SPN)hemoptysis
Beyond the preview
Go deeper on ChiCTR2500110217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110217.